Wockhardt Ltd shares plunge over 8% amid profit booking pressure after a 50% rally

Shares of Pharmaceutical major Wockhardt fell over 8% on Tuesday after rallying over 50% in the past few trading sessions. The shares traded 8.5% lower at ₹1,969 apiece on the NSE at 1:30 pm. The remains in focus after it secured a milestone approval from the US-FDA for an anti-biotic drug.

Alongside this special announcement, the company also announced quarterly results last week. For the quarter ending March 2026, the company’s revenue jumped 30% YoY to ₹965 crore as compared to ₹743 crore in the same period last year.

At the operational level, the EBITDA for the quarter stood at ₹196 crore as compared to ₹79 crore in the quarter ending March 2025, up 179%.At the bottom-line level, the company posted a turnaround by reporting a net profit of ₹164 crore as against a net loss of ₹64 crore in the same period last year.

The robust growth in the topline for the quarter was fueled by Biotech Insulin segment in the Emerging market and the Latam operations contributed significant traction to the segment growth.

Beyond the robust quarterly performance, the company’s major achievement of securing USFDA approval for its ZAYNICH drug cheered the investor sentiments.

Commenting on the achievement, Dr Habil Khorakiwala, Founder and Chairman of Wockhardt Group, said, “This approval is a significant realisation of our mission to provide patients with novel antibiotics that help to address one of the most urgent global health threats—antimicrobial resistance.”

“Furthermore, ZAYNICHTM is the first New Chemical Entity fully developed and commercialised by an Indian pharmaceutical company to receive an FDA approval, representing a historic milestone not only for Wockhardt, but for the Indian pharmaceutical industry.”

However, today’s fall in the share price is largely linked to profit booking sentiment after a euphoric rally of over 50% in merely five six trading days.